XSHE
000153
Market cap452mUSD
Dec 05, Last price
6.80CNY
1D
-1.16%
1Q
0.59%
Jan 2017
-47.25%
IPO
-19.72%
Name
Anhui Fengyuan Pharmaceutical Co Ltd
Chart & Performance
P/E
19.65
P/S
0.74
EPS
0.35
Div Yield, %
3.05%
Shrs. gr., 5y
8.28%
Rev. gr., 5y
5.76%
Revenues
4.28b
+0.21%
Net income
161m
+0.97%
CFO
126m
-50.45%
Dividend
Jun 07, 20240.21 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biological pharmacy, chemical pharmacy, and traditional Chinese medicines primarily in China. It offers antipyretic-analgesic, cardiovascular, antibiotic, nervous system, anti-tumor, antiulcer, and hormone drugs, as well as nutraceuticals. The company also provides general medicines for vitamin and mineral deficiency; medicines for resisting parasitic diseases and microorganisms; coenzymes; and antiviral and uterine contractive medicines. In addition, it offers sedative-hypnotic drugs; drugs for curing mesenteric stress syndrome; drugs for lowering blood pressure; and drugs for curing benign prostatic hyperplasia. The company also exports its products to Europe, North America, Africa, Southeast Asia, and Central Asia. Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in 1997 and is based in Hefei, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||